drugset / Trial / NCT06299033
A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke
NaSingle-groupOpen-labelTreatment
Summary
The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects with stable chronic ischemic stroke.
Timeline
- Start
- 2023-11-09
- Primary completion
- 2024-08-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hNPC01 | Cell therapy | 1.5e+07 cells | Other |
| Subject | hNPC01 | Cell therapy | 3e+07 cells | Other |
| Subject | hNPC01 | Cell therapy | 6e+07 cells | Other |